About 20%–30% of NSCLC patients harboring activating EGFR mutations have no good initial clinical responses to EGFR-TKIs, but almost all patients finally develop acquired resistance after 10–12 months of treatment [11,12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.